Physician profile
Jianping Lin
NPI 1265871636
$1,381.10
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $95.21 · 2021: $61.55 · 2022: $98.97 · 2023: $244 · 2024: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $259.85 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $209.44 | 2020-2024 | Keytruda, Welireg, Lynparza |
| Foundation Medicine, INC. | $167.38 | 2019-2023 | |
| Lilly USA, LLC | $157.04 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $92.72 | 2023-2024 | Xtandi |
| Janssen Pharmaceuticals, INC | $76.22 | 2019-2020 | |
| Springworks Therapeutics, INC. | $68.67 | 2024 | Ogsiveo |
| Eisai INC. | $59.91 | 2020-2024 | |
| Ortho-Clinical Diagnostics, INC. | $44.32 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $30.19 | 2019 | |
| Daiichi Sankyo INC. | $30.06 | 2022 | |
| Pfizer INC. | $29.62 | 2024 | |
| Emd Serono, INC. | $27.84 | 2024 | |
| Seagen INC. | $25.34 | 2023 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $22.74 | 2024 | Fruzaqla |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $22.35 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.54 | 2020 | |
| Cepheid | $18.86 | 2021 | |
| Abbott Laboratories | $18.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jianping Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.